CXCR4 and plasma cell myeloma: Several CXCR4-antagonist small-molecule compounds have also been investigated, with Plerixafor (AMD3100, Mozobil®) being approved by the US Food and Drug Administration (FDA) in 2008 for multiple myeloma and lymphoma.